Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BriaCell Therapeutics Corp.BCTX · Entity 7454 | Director · President, CEO | December 23, 2022 | December 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BriaCell Therapeutics Corp.
Report date December 23, 2022 · Filed December 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.31 · Expires 2026-02-25 | Direct | 29,802 |
Reported balance
After 2022-12-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-23 · Purchase · Acquired 2,530 · Balance 29,802 F1: The price reported in Column 8 is a weighted average price. These Warrants were purchased in multiple transactions at prices ranging from $1.97 to $2.00 per Warrant, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Warrants purchased at each separate price within the ranges set forth herein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 8 is a weighted average price. These Warrants were purchased in multiple transactions at prices ranging from $1.97 to $2.00 per Warrant, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Warrants purchased at each separate price within the ranges set forth herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 23, 2022 Filed Dec 28, 2022 20:22 UTC | BriaCell Therapeutics Corp. BCTX · Entity 7454 | PurchaseWarrant · Derivative | 2,530 | $1.94 Strike: $5.31 | $4,908.20 |
DisclosureSEC source: 0001493152-22-036643 · ownership.xml · derivative · entry 1 Williams William V. · CIK 0001939302 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,802 Underlying: Common Shares · 2,530 shares Expires 2026-02-25 F1 · price: The price reported in Column 8 is a weighted average price. These Warrants were purchased in multiple transactions at prices ranging from $1.97 to $2.00 per Warrant, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Warrants purchased at each separate price within the ranges set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.